IL164281A0 - Epitope constructs comprising antigen presenting cell targeting mechanisms - Google Patents

Epitope constructs comprising antigen presenting cell targeting mechanisms

Info

Publication number
IL164281A0
IL164281A0 IL16428103A IL16428103A IL164281A0 IL 164281 A0 IL164281 A0 IL 164281A0 IL 16428103 A IL16428103 A IL 16428103A IL 16428103 A IL16428103 A IL 16428103A IL 164281 A0 IL164281 A0 IL 164281A0
Authority
IL
Israel
Prior art keywords
antigen presenting
presenting cell
cell targeting
epitope constructs
targeting mechanisms
Prior art date
Application number
IL16428103A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of IL164281A0 publication Critical patent/IL164281A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL16428103A 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms IL164281A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945402P 2002-04-01 2002-04-01
PCT/US2003/010033 WO2003084467A2 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Publications (1)

Publication Number Publication Date
IL164281A0 true IL164281A0 (en) 2005-12-18

Family

ID=28791953

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16428103A IL164281A0 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Country Status (6)

Country Link
JP (1) JP2005536987A (xx)
AU (1) AU2003224819A1 (xx)
CA (1) CA2478930A1 (xx)
IL (1) IL164281A0 (xx)
MX (1) MXPA04009554A (xx)
WO (1) WO2003084467A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
WO2004005463A2 (en) * 2002-07-03 2004-01-15 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
CA2514058C (en) * 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
ES2415336T3 (es) * 2003-04-11 2013-07-25 Survac Aps Vacuna terapéutica contra el cáncer
GB0318247D0 (en) * 2003-08-05 2003-09-10 Royal Veterinary College Antigen delivery system
EP1863529A1 (en) * 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
EP1910827A4 (en) * 2005-07-15 2010-02-03 Novartis Ag MOLECULAR MOTIVES ASSOCIATED WITH PATHOGENS (PAMP)
ATE545708T1 (de) * 2005-11-14 2012-03-15 Univ Laval Krebsantigen mage-a9 und verwendungen davon
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
DK2476435T3 (en) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Immunogenic peptides and their use in immune disorders
WO2008118017A2 (en) 2007-03-26 2008-10-02 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
PT2567707T (pt) * 2007-07-27 2016-12-27 Immatics Biotechnologies Gmbh Composição de péptidos associados a tumores e vacina anticancro relacionada
JP2012511033A (ja) * 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
KR20150128900A (ko) 2013-03-15 2015-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-23을 갖는 백신
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
WO2016196383A1 (en) * 2015-06-01 2016-12-08 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
WO2017165542A1 (en) * 2016-03-22 2017-09-28 University Of Florida Research Foundation, Inc. Methods, kit, and compositions for enhancing cellular therapy
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Also Published As

Publication number Publication date
MXPA04009554A (es) 2005-01-25
AU2003224819A1 (en) 2003-10-20
CA2478930A1 (en) 2003-10-16
JP2005536987A (ja) 2005-12-08
WO2003084467A3 (en) 2006-07-20
WO2003084467A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
IL164281A0 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
HK1077226A1 (en) Human monoclonal antibodies against cd25
PT1740207E (pt) Vectores e construções de entrega de antigénios
EP1633785A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
AP2006003510A0 (en) Modified human IGF-1R antibodies.
EP1572131A4 (en) ANTIBODY THERAPY
IL165256A0 (en) Neutralizing human anti-igfr antibody
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
EP1550453A4 (en) PREPARATION OF CANCER ANTIGEN PEPTIDES
EP1571909A4 (en) OPTIMIZED CONSTRUCTIONS WITH SEVERAL EPITOPES AND USES THEREOF
EP1461001A4 (en) EPITOPE ASSOCIATED WITH CANCER
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
EP1597356A4 (en) CELLS HAVING THE CD14 + ANTIGEN OF CULTURE
GB0215287D0 (en) 5T4 antigen expression
EP1646401A4 (en) SPECIFIC HUMAN ANTIBODIES
AU2002365187A8 (en) Epitope synchronization in antigen presenting cells
EP1687398A4 (en) EXPRESSION CONSTRUCTS THAT DEPEND ON HIV AND USES THEREOF
GB0313064D0 (en) Mycobacterial vaccine
GB0226878D0 (en) Antibodies
AU2002951847A0 (en) Antifungal antibody constructs
AU2003304720A1 (en) Peptides for targeting the prostate specific membrane antigen
GB0321288D0 (en) Structured polypeptide constructs
GB0325391D0 (en) Human monoclonal antibodies
GB0204988D0 (en) Padded envelope
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa